Explore

Trendline Trendline
Harbour BioMed Reports Positive Profit Alert for 2026, Driven by Strategic Collaborations

Harbour BioMed Reports Positive Profit Alert for 2026, Driven by Strategic Collaborations

Harbour BioMed Reports Positive Profit Alert for 2026, Driven by Strategic Collaborations
Reuters Reuters
Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK.
Trendline Trendline
Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Strategic Focus

Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Strategic Focus

Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Strategic Focus
Trendline Trendline
YouTube Ad Revenue Grows 13% in Q2 2026, Boosting Alphabet's Earnings

YouTube Ad Revenue Grows 13% in Q2 2026, Boosting Alphabet's Earnings

YouTube Ad Revenue Grows 13% in Q2 2026, Boosting Alphabet's Earnings
Trendline Trendline
Alphabet's Stock Drops Over 6% Despite Q2 Earnings Beat Due to Capex Growth

Alphabet's Stock Drops Over 6% Despite Q2 Earnings Beat Due to Capex Growth

Alphabet's Stock Drops Over 6% Despite Q2 Earnings Beat Due to Capex Growth
Trendline Trendline
Thyora Therapeutics Launches Platform for Precision Covalent Drug Discovery

Thyora Therapeutics Launches Platform for Precision Covalent Drug Discovery

Thyora Therapeutics Launches Platform for Precision Covalent Drug Discovery
Trendline Trendline
Quest Diagnostics Announces Strong Q2 2026 Financial Results and Raises Full-Year Guidance

Quest Diagnostics Announces Strong Q2 2026 Financial Results and Raises Full-Year Guidance

Quest Diagnostics Announces Strong Q2 2026 Financial Results and Raises Full-Year Guidance
TheStreet TheStreet
Tempus makes $1.5B bet to corner cancer-test market

Tempus makes $1.5B bet to corner cancer-test market

Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion.  The move hands Tempus full control of a test that spots cancer ...
Trendline Trendline
Dimension Capital Secures $800 Million for AI-Driven Biotech Investments

Dimension Capital Secures $800 Million for AI-Driven Biotech Investments

Dimension Capital Secures $800 Million for AI-Driven Biotech Investments
Trendline Trendline
Broadcom's Financial Strategy Highlights AI Revenue Growth

Broadcom's Financial Strategy Highlights AI Revenue Growth

Broadcom's Financial Strategy Highlights AI Revenue Growth
Trendline Trendline
Zai Lab to Release Q2 2026 Financial Results and Corporate Updates

Zai Lab to Release Q2 2026 Financial Results and Corporate Updates

Zai Lab to Release Q2 2026 Financial Results and Corporate Updates
Trendline Trendline
AlTi Global Inc. Expands Investment in Taiwan Semiconductor Manufacturing, Reflecting Strong Market Confidence

AlTi Global Inc. Expands Investment in Taiwan Semiconductor Manufacturing, Reflecting Strong Market Confidence

AlTi Global Inc. Expands Investment in Taiwan Semiconductor Manufacturing, Reflecting Strong Market Confidence